Source: Yahoo!
CALGARY, Alberta and BATON ROUGE, La., May 31, 2022 (GLOBE NEWSWIRE) -- Skymount Medical, a drug discovery
company using an artificial intelligence (AI) platform developed by Louisiana State University (LSU) researchers to
repurpose and build new drugs for innovative new therapies, announced today that its DeepDrug™ AI platform to
repurpose and build new drugs for innovative new therapies, announced today that its DeepDrug™ AI platform to
accelerate drugdiscovery has garnered a Silver Stevie® Award in the Artificial Intelligence/Machine Learning Solution
category of the 20th Annual American Business Awards®. This recognition further positions DeepDrug™ as a global
leader in artificial intelligence.
“We are honored and gratified to be among the elite group of companies recognized for their achievements,” said Zubin
Kothawala, chief executive officer of Skymount Medical. “It is especially meaningful that the judges’ comments included
words like ‘revolutionary’ and ‘sophisticated’ when describing our computer-aided drug design software that uses key
components to deliver an efficient, state-of-the-art compound generation that significantly shortens the timelines and
reduces the cost for new drug development. Receiving this prestigious award validates our commitment to the important
work of advancing the development of improved medicines using DeepDrug™ and providing greater access to cutting-
edge therapeutics.”
“We are excited to see the LSU DeepDrug™ technology and Skymount Medical receive this recognition,” said LSU
Associate Vice President of Research and Innovation and Ecosystem Development Andrew Maas. “We look forward to
the many applications this AI platform can impact for good.”
The American Business Awards is the premier business awards program in the United States. All organizations
operating in the U.S. are eligible to submit nominations, whether they are public or private, for-profit or non-profit, large
or small.
Nicknamed “the Stevies” from the Greek word for “crowned,” the awards will be presented at a gala ceremony at the
Marriott Marquis Hotel in New York on Monday, June 13.
For a full list of winners, click here.
About DeepDrug™
The DeepDrug™ artificial intelligence platform was developed by an interdisciplinary team of Louisiana State University
(LSU) researchers led by Supratik Mukhopadhyay, professor in the LSU Department of Environmental Sciences, and
Michal Brylinski, associate professor in the LSU Department of Biological Sciences with a joint appointment in the LSU
Center for Computation & Technology. The DeepDrug™ platform delivers a state-of-the-art compound and formula
generation capability that greatly reduces the time and cost associated with traditional drug discovery.
About Skymount Medical Inc.
Skymount Medical is an artificial intelligence and biotechnology company that uses DeepDrug™️, a patent-pending AI
platform,to accelerate drug discovery and development. Alongside Louisiana State University, the company is currently
developing combination therapies to fight COVID-19 and all coronavirus strains. Additionally, Skymount Medical is
planning to develop therapeutics for other infectious diseases as well as new antibiotics that target antibiotic-resistant
bacteria and rare diseases. Visit skymountmed.com to learn more.
